GE HealthCare (GEHC): Backlog and PDx Growth vs. Margin Pressure

Thesis

GE HealthCare Technologies Inc. (GEHC) fits a balanced, moderate-risk medtech profile: a large installed base, recurring service and consumables revenue, leadership in imaging, and a faster-growing pharmaceutical diagnostics arm. The core bull case rests on three facts. First, the company exited 2025 with record backlog of $21.8B and a 1.07x trailing 12-month book-to-bill ratio, which gives the revenue base real ballast. Second, management guided 2026 adjusted EPS to $4.80 to $5.00 after the Q1 reset, still above 2025 adjusted EPS of $4.59. Third, free cash flow remains meaningful at about $1.5B in 2025, with FCF yield at 7.9%, which gives GEHC room to invest, deleverage, repurchase shares, and tuck in acquisitions.

The caution is just as clear. Q1 2026 revenue rose 7.4% to $5.13B, but adjusted EBIT fell 2.1% to $691M, adjusted EBIT margin dropped 150 bps to 13.5%, and adjusted EPS slipped to $0.99 from $1.02. Management then cut full-year adjusted EBIT margin guidance to 15.4% to 15.7% from 15.8% to 16.1%, lowered adjusted EPS guidance to $4.80 to $5.00 from $4.95 to $5.15, and reduced free cash flow guidance to about $1.6B from about $1.7B. That is not a broken story, but it is a reminder that GEHC is still working through tariff, inflation, and supplier friction.

The investment setup is therefore not about heroic assumptions. It is about whether GEHC can convert backlog, product launches, and PDx momentum into steadier margin expansion after a messy start to 2026. At roughly 15.1x trailing earnings and 13.9x forward earnings, the stock is not priced like a premium-growth medtech name. It is priced more like a solid operator that still has something to prove. That is exactly why the shares remain interesting on a medium-term horizon.

Company Overview

GE HealthCare is a global medical technology company headquartered in Chicago, with about 54,000 employees and customers in over 160 countries. The company was spun from General Electric in January 2023 and now operates across four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its portfolio spans MRI, CT, ultrasound, X-ray, molecular imaging, patient monitoring, anesthesia, contrast media, radiopharmaceuticals, software, AI-enabled tools, and services.

That breadth matters. Hospitals do not buy imaging hardware in a vacuum. They buy uptime, workflow, service response, software integration, and increasingly a path from diagnosis to therapy selection. GEHC’s 10-K says it has about 9,700 sales professionals and 8,900 field service engineers, which is a serious commercial and service footprint. In medtech, that kind of field presence is less glamorous than AI slides and far more useful when a scanner goes down on a Monday morning.

Financially, GEHC generated $20.63B of revenue in 2025, up from $19.67B in 2024. EBITDA was $3.64B, operating margin was 15.73%, and net margin was 10.1%. Market capitalization stands near $31.3B. The company also produced $1.99B of operating cash flow and about $1.51B of annual free cash flow in 2025, even with tariff pressure weighing on margins and cash conversion.

Business Segment Deep Dive

Imaging is the anchor business. Segment data for 2025 shows Imaging revenue of $9.25B, or 60.7% of the reported segment total. In Q4 2025, Imaging organic revenue grew 5.3%, driven by execution in the U.S. and EMEA, particularly in nuclear medicine. In Q1 2026, Imaging revenue reached $2.299B with 3.8% organic growth, while segment EBIT margin fell to 7.8% from 9.3% as tariffs offset volume gains. This is the classic GEHC pattern right now: demand is holding up, but cost friction is eating part of the operating leverage.

AVS is the cleaner growth-and-margin story. The segment includes specialized ultrasound and procedural guidance. In Q4 2025, management said AVS delivered mid-single-digit growth, helped by products such as VividPioneer. In Q1 2026, AVS revenue was $1.239B with 4.4% organic growth, segment EBIT rose 14.5% to $299M, and margin expanded 120 bps to 22.3%. That margin profile stands out. AVS is doing what investors want the broader company to do: convert innovation into mix improvement and profit growth.

PCS is the problem child. The segment generated $3.09B of 2025 revenue, or 20.3% of the segment total. In Q4 2025, organic revenue fell 1.1% and margin was hit by unfavorable mix and tariffs, though shipments recovered from a prior product hold. In Q1 2026, PCS revenue fell to $704M, down 8.1% organically, while segment EBIT collapsed to $10M from $48M and margin fell to 1.4% from 6.4%. Management said the decline was mainly due to select large monitoring installations shifting into 2H 2026, and that orders grew in Q1. That explanation is plausible, but the segment still needs proof, not patience.

PDx is the growth kicker. Segment revenue was $2.90B in 2025, up from $2.51B in 2024, lifting its share of segment revenue to 19.0% from 17.3%. In Q4 2025, PDx organic sales growth was 12.7%, driven by contrast media, pricing, and U.S. radiopharmaceutical adoption. In Q1 2026, PDx revenue climbed to $770M with 9.7% organic growth. Margin dropped sharply to 25.6% from 32.4% because of a supplier issue and planned investments, but the top-line trajectory remains strong. This segment gives GEHC a growth profile that pure imaging peers do not fully replicate.

Flagship Product Analysis

The most important flagship product story is Flyrcado, GEHC’s radiopharmaceutical for myocardial perfusion PET imaging. Management said on the Q4 2025 call that weekly doses reached 220 in the week ended January 23, 2026, with contract manufacturing partners operating at about 95% on-time delivery. By Q1 2026, the investor presentation said Flyrcado doses had grown nearly 80% since late January. That is a meaningful early ramp in a product category where logistics matter as much as clinical appeal.

Why Flyrcado matters is simple. GEHC is not just selling an imaging machine. It is pairing hardware, tracers, workflow, and clinical adoption in a way that can deepen customer relationships and create recurring revenue. Management also noted that the American Society of Nuclear Cardiology recommended PET over SPECT as the preferred imaging modality, reinforcing a broader modality shift that supports the product’s adoption curve.

Outside PDx, VividPioneer is another notable product. Management said the cardiovascular ultrasound platform has been contributing to strong AVS growth, and AVS posted 22.3% segment EBIT margin in Q1 2026. Photonova Spectra, the company’s photon-counting CT system, also received regulatory clearance in the U.S. and Japan. Those launches matter less for immediate 2026 revenue than for 2027 mix. Management said revenue contribution from key imaging new product introductions is expected to begin in the first half of 2027. In plain English, the pipeline is real, but the revenue clock is not instant.

Innovation & Competitive Advantage

GEHC’s core competitive advantage is not one device. It is the combination of installed base, service reach, regulatory trust, and portfolio breadth. The company’s 10-K says it is the only diagnostic imaging company with a full portfolio of contrast media and radiopharmaceuticals. Management calls this the D3 strategy: devices plus drugs plus digital. That combination is strategically attractive because it lets GEHC participate in more of the clinical workflow and capture more recurring revenue around each installed system.

Innovation spending is not trivial. Management said GEHC deployed more than $1.7B of innovation investment in 2025, while the 10-K says the company employs about 11,100 engineers and scientists worldwide. The three-year vitality rate for new products reached 55%, up about 5 points from the prior year, meaning 55% of revenue is coming from newer products. That is a strong signal that the portfolio is not aging in place.

Acquisitions are also part of the moat-building plan. Management said the planned Intelerad acquisition is expected to add about $270M of revenue in the first full year of ownership, with low-double-digit growth and adjusted EBITDA above 30%. The strategic logic is clear: more cloud-first imaging software, more SaaS, more recurring revenue, and tighter workflow integration. Near-term integration risk exists, but the direction is sensible. In medtech, software is where differentiation gets stickier and margins usually get friendlier.

Operations & Supply Chain

Operations are central to the GEHC story because 2025 and early 2026 were shaped by tariffs, supplier issues, and logistics. Management’s Heartbeat operating system is the company’s lean framework for safety, quality, delivery, cost, and innovation. That sounds like corporate wallpaper until it shows up in numbers. In the back half of 2025, management said Heartbeat helped drive an average monthly improvement of 25% in past-due backlog versus the prior year, supporting better sales and cash conversion.

Tariff mitigation was also concrete. CFO Jay Saccaro said the company shifted a PET/CT line from the Middle East to the U.S. and a surgery line from Asia to the U.S., while working with contract manufacturers to reposition production to more favorable geographies. In Q4 2025 alone, tariffs cost about $100M at the EBIT line and about $0.17 in adjusted EPS. For full-year 2025, tariff impact was about $245M to EBIT and $0.43 to adjusted EPS. Those are not rounding errors. They are the difference between a clean margin story and the one investors actually got.

The 10-K says GEHC has manufacturing, assembly, and pharmaceutical production in 44 facilities across 17 countries. That scale supports resilience, but it also exposes the company to trade policy and component inflation. In Q1 2026, management quantified inflation headwinds at roughly $250M, including about $100M from memory chips, $100M from oil and freight, and about $50M from other inputs. More than half is expected to be offset by price and cost actions, but that still leaves a decent-sized bruise.

Market Analysis

GEHC operates in a large and durable market. Company materials put its addressable market at about $100B by 2025, with historical segment sizes of $44B in Imaging, $12B in Ultrasound, $18B in Patient Care Solutions, and $10B in Pharmaceutical Diagnostics. Broader medical device market estimates run above $500B globally with roughly 5% to 7% growth, but GEHC’s practical hunting ground is the higher-end diagnostic and monitoring ecosystem where installed base, service capability, and regulatory trust matter most.

Several demand trends support the company. Imaging procedure demand has been expected to grow 4% to 5% annually, contrast media demand is expected by company materials to double over the next decade, and providers continue to invest in workflow tools that reduce labor friction. Management said the capital equipment environment remained healthy in Q4 2025, with strong demand in the U.S. and EMEA. It also cited an increase in large U.S. customers planning to invest in capital equipment in 2026.

The market is also shifting from standalone hardware to integrated platforms. AI-enabled reconstruction, cloud imaging, enterprise software, and vendor-agnostic clinical workflows are no longer side dishes. They are becoming part of the main course. GEHC’s mix of equipment, diagnostics, software, and service positions it well for that shift. The risk is that competitors are chasing the same trend, so execution, not strategy slides, will decide who keeps pricing power.

Customer Profile

GEHC serves hospitals, health systems, imaging centers, researchers, and public, private, academic, and government institutions. The 10-K says its commercial model combines direct sales, strategic account teams, inside sales, distributors, and more than 5,000 indirect third-party partners. That mix matters because buying behavior differs sharply between a flagship academic center and a regional hospital network.

The company’s strongest customer relationships appear to be enterprise-level. Management highlighted more than $7B in enterprise deals globally since the spin, a seven-year agreement with the University of Rochester Medical Center, a multiyear agreement with Indonesia’s Ministry of Health, and a 20-year collaboration with Nuffield Health in the U.K. These are not one-box transactions. They are system relationships that often include service, monitoring, software, and multimodality equipment. That tends to improve retention and service attach over time.

Customer economics also favor incumbents. Imaging systems are expensive, training-intensive, and embedded in clinical workflow. Once a provider standardizes around a vendor, switching is disruptive. GEHC’s service business grew mid-single digits in 2025, and management said many large deals include service components with attractive margins. That recurring layer is one of the company’s most important stabilizers.

Competitive Landscape

GEHC’s 10-K identifies Siemens Healthineers, Philips Healthcare, Canon, United Imaging, and Mindray among its primary global competitors. In PDx, the company competes with Bayer, Bracco, Guerbet, Lantheus, and Curium. This is a serious field. Nobody here is bringing a butter knife to a gunfight.

GEHC’s edge versus peers is breadth plus installed base. It can sell imaging hardware, service contracts, monitoring, software, and pharmaceutical diagnostics into the same account. That matters in enterprise deals where procurement wants fewer vendors, tighter integration, and predictable uptime. The company also has a global field service network that smaller challengers cannot easily replicate.

Its weaker point is not market access but consistency. PCS underperformance, tariff exposure, and the Q1 2026 margin reset show that GEHC still has operational work to do. Competitors are also investing heavily in AI, workflow software, and connected care. So while GEHC has a credible moat, it is not a toll bridge with no alternate route. The moat is real, but it needs maintenance.

Macro & Geopolitical Landscape

The biggest macro issue for GEHC right now is not demand destruction. It is cost pressure. Tariffs hit 2025 adjusted EBIT by about $245M and adjusted EPS by $0.43. In Q1 2026, margin pressure continued, and management cited a roughly $250M inflation headwind for the year, including memory chips, oil and freight, and other inputs. This is why revenue growth has not translated cleanly into earnings growth.

China is the key geopolitical swing factor. Management said Q1 2026 in China was in line with expectations and improved sequentially, but the company still expects China sales to be down year over year in 2026. On the Q4 2025 call, management also noted better VBP win rates and a more robust imaging funnel, yet chose a prudent stance in guidance. That is the right posture. China can move from headwind to help, but it is not prudent to underwrite the stock on that turn alone.

Healthcare capital spending has held up better than many cyclical industrial categories, especially in the U.S. and EMEA, which management called out as strong in late 2025. That resilience supports GEHC’s backlog and service model. Still, the company remains exposed to trade policy, reimbursement changes, data privacy regulation, and supply chain disruptions. In other words, the demand tide is decent, but the operating waters are choppy.

Balance Sheet Health

Income Statement Strength

Estimates Outlook

Valuation Assessment

Target Prices & Recommendation

Closing

GE HealthCare is a good business in the middle of a proving period. The company has real strengths: a broad installed base, global service reach, strong positions in imaging and diagnostics, rising exposure to software and recurring revenue, and a product pipeline that looks meaningful rather than cosmetic. The numbers support that view. Revenue reached $20.63B in 2025, free cash flow was about $1.51B, backlog hit a record $21.8B, and PDx plus AVS continue to show attractive momentum.

The issue is that the path is not perfectly smooth. Q1 2026 showed that tariffs, supplier friction, and inflation can still knock margins off course, and PCS remains a weak link. That keeps the stock from earning a premium valuation today. Still, at a forward P/E below 14x and with our fair value estimate of $88, GEHC offers a solid risk-reward profile for investors willing to hold through some operational noise.

In short, GEHC is not a moonshot and does not need to be. It is a large, durable medtech platform with enough growth drivers to compound value if management executes. For a moderate-risk investor with a medium-term horizon, that is a setup worth owning, not merely admiring from a distance.